Table 2.
Baseline characteristics of the study population
| Characteristics | N data available | CSF and/or MRI available (N = 287) | Only MRI available (N = 180) | CSF available (N = 107) | p-value |
|---|---|---|---|---|---|
| Demographics | |||||
| Age, years | 287 | 70.9 (6.6) | 71.6 (6.2) | 69.8 (7.0) | 0.02 |
| Female | 287 | 147 (51.2%) | 100 (55.6%) | 47 (43.9%) | 0.06 |
| Education, years | 287 | 10.5 (3.7) | 10.6 (3.8) | 10.4 (3.7) | 0.62 |
| Cognition | |||||
| MMSE score | 286 | 26.6 (2.0) | 26.7 (2.0) | 26.6 (1.9) | 0.94 |
| NTB composite | 284 | 0.012 (0.682) | − 0.010 (0.711) | 0.050 (0.630) | 0.48 |
| NTB memory | 283 | 0.014 (0.848) | 0.021 (0.885) | 0.003 (0.786) | 0.87 |
| NTB executive functioning | 281 | 0.007 (0.681) | − 0.046 (0.656) | 0.095 (0.718) | 0.09 |
| NTB total | 283 | 0.004 (0.549) | − 0.003 (0.561) | 0.017 (0.532) | 0.77 |
| CDR-SB | 259 | 1.76 (1.12) | 1.91 (1.17) | 1.53 (1.02) | 0.01 |
| Biomarkers and APOE | |||||
| APOE ε4 carrier | 260 | 162/260 (62.3%) | 97/156 (62.2%) | 65/104 (62.5%) | 0.96 |
| MTA score | 279 | 2 [1–4] | 3 [1–4] | 2 [1–3] | 0.11 |
| Abnormal MTA | 279 | 241/279 (86.4%) | 155/180 (86.1%) | 86/99 (86.9%) | 0.86 |
| CSF Aβ42, pg/ml | 107 | 412 (242) | NA | 412 (242) | NA |
| CSF Aβ42/40 ratio | 107 | 0.63 (0.27) | NA | 0.63 (0.27) | NA |
| Abnormal Aβ | 107 | 94/107 (87.9%) | NA | 94/107 (87.9%) | NA |
| CSF t-tau, pg/ml | 107 | 616 (276) | NA | 616 (276) | NA |
| Abnormal t-tau | 107 | 92/107 (86.0%) | NA | 92/107 (86.0%) | NA |
| CSF p-tau, pg/ml | 107 | 78 (29) | NA | 78 (29) | NA |
| Abnormal p-tau | 107 | 74/107 (69.2%) | NA | 74/107 (69.2%) | NA |
Data are mean (SD), median [IQR], or N (%). p-values are shown for comparisons between participants with only MRI available and those with centrally analyzed CSF. Abnormal MTA defined as a score of ≥ 1; abnormal Aβ as CSF Aβ42 < 450 pg/ml and/or CSF Aβ42/40 ratio < 1; abnormal t-tau as CSF t-tau > 350 pg/ml; abnormal p-tau as CSF p-tau > 60 pg/ml
Abbreviations: Aβ42, β-amyloid 1–42; Aβ40, β-amyloid 1–40; Aβ42/40 ratio, Aβ42/40 × 10; APOE, apolipoprotein E; CDR-SB, Clinical Dementia Rating-Sum of Boxes; CSF, cerebrospinal fluid; MMSE, Mini-Mental State Examination; MRI, magnetic resonance imaging; MTA, medial temporal lobe atrophy, visual rating; NTB, Neuropsychological Test Battery; p-tau, tau phosphorylated at threonine 181; t-tau, total tau